Cyclooxygenase (COX) inhibitors and the intestine

Journal of Veterinary Internal Medicine

Volumn 21, Issue 3, 2007, Pages 367-377

  Little, Dianne ^a   Jones, Samuel L ^a   Blikslager, Anthony T ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Heat shock protein; Nonsteroidal anti inflammatory drugs; Nuclear factor KB; p38 Mitogen activated protein kinases; Peroxisome proliferator activated receptor gamma

Indexed keywords

HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE B;

ANIMAL; ARTICLE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; INTESTINE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEAT-SHOCK PROTEINS; INTESTINES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 34249297006     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[367:CCIATI]2.0.CO;2     Document Type: Article

References (88)

1. Vane JR. The fight against rheumatism: From willow bark to COX-1 sparing drugs. J Physiol Pharm 2000;51:573-586.
2. Vane JR, Bolting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-258.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 1971;231:232-235.
4. Hemler M, Lands WEM, Smith WL. Purification of the cyclo-oxygenase that forms prostaglandins: Demonstration of two forms of iron in the holoenzyme. J Biol Chem 1976;251:5575-5579.
5. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthesis is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696.
6. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000;355:646-648.
7. Chandrasekharan NV, Dai H, Roos KL, et al. Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proc Natl Acad Sci USA 2002;99:13926-13931.
8. Qin N, Zhang SP, Reitz TL, et al. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: Evidence for intron 1 retention. J Pharmacol Exp Ther 2005;315:1298-1305.
9. Davies NM, Good RL, Roupe KA, et al. Cyclooxygenase-3: Axiom, dogma, anomaly, enigma or splice error? - Not as easy as 1, 2, 3. J Pharm Pharmaceut Sci 2004;7:217-226.
10. Nurmi JT, Puolakkainen PA, Rautonen NE. Intron 1 retaining cyclooxygenase 1 splice variant is induced by osmotic stress in human intestinal epithelial cells. Prostaglandins Leukot Essent Fatty Acids 2005;73:343-350.
11. Roos KLT, Simmons DL. Cyclooxygenase variants: The role of alternative splicing. Biochem Biophys Res Comm 2005;338:62-69.
12. Martin GR, Wallace JL. Gastrointestinal inflammation: A central component of mucosal defense and repair. Exp Biol Med (Maywood) 2006;231:130-137.
13. Hiratsuka T, Futagami S, Tatsuguchi A, et al. COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice. Scand J Gastroenterol 2005;40:903-913.
14. Bhandari P, Bateman AC, Mehta RL, et al. Mucosal expression of cyclooxygenase isoforms 1 and 2 is increased with worsening damage to the gastric mucosa. Histopathology 2005;46:280-286.
15. Hoffmann U, Banas B, Kruger B, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human renal allograft rejection - A prospective study. Transpl Int 2006;19:203-212.
16. Tomlinson JE, Wilder BO, Young KM, et al. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 2004;65:761-769.
17. DeLong CJ, Smith WL. An intronic enhancer regulated COX-1 gene expression. Biochem Biophys Res Commun 2005;338:53-61.
18. Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 2005;33:724-727.
19. Porcher C, Horowitz B, Ward SM, et al. Constitutive and functional expression of cyclooxygenase 2 in the murine proximal colon. Neurogastroenterol Motil 2004;16:785-799.
20. Haworth R, Oakley K, McCormack N, et al. Differential expression of COX-1 and COX-2 in the gastrointestinal tract of the rat. Toxicol Pathol 2005;33:239-245.
21. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation- associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996;98:2076-2085.
22. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998;123:795-804.
23. Murakami M, Kambe T, Shimbara S, et al. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 1999;274:3103-3115.
24. Schuligoi R, Grill M, Heinemann A, et al. Sequential induction of prostaglandin E and D synthases in inflammation. Biochem Biophys Res Commun 2005;335:684-689.
25. Bianchi A, Moulin D, Sebillaud S, et al. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR) gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: Evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14 prostaglandin J2. Arthritis Res Ther 2005;7:R1325-1337.
26. Straus DS, Glass CK. Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med Res Rev 2001;21:185-210.
27. Fitzgerald GA, Loll P. COX in a crystal ball: Current status and future promise of prostaglandin research. J Clin. Invest 2001;107:1335-1337.
28. Bertolini A, Ottani A, Sandrini M. Dual acting antiinflammatory drugs: A reappraisal. Pharmacol Res 2000;44:437-450.
29. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648.
30. Kulp SK, Yang YT, Hung CC, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-1451.
31. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
32. Zhang X, Morham SG, Langenbach R, et al. Malignant transformation and antineoplastic actions of nonsteroidal antiin-flammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-159.
33. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-2072.
34. Geisslinger G, Ferreira SH, Menzel S, et al. Antinociceptive actions of R(-)-flurbiprofen-a non-cyclooxygenase inhibiting 2-arylpropionic acid-in rats. Life Sci 1994;54:PL173-PL177.
35. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 2004;9:667-676.
36. Zhu J, Huang JW, Tseng PH, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-4318.
37. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-390.
38. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
39. Hou CC, Hung SL, Kao SH, et al. Celecoxib induces hemeoxygenase expression in glomerular mesangial cells. Ann NY Acad Sci 2005;1042:235-245.
40. Attuwaybi BO, Kozar RA, Moore-Olufemi SD, et al. Heme oxygenase-1 induction by hemin protects against gut ischemia/ reperfusion injury. J Surg Res 2004;118:53-57.
41. Deshane J, Wright M, Agarwal A. Heme oxygenase-1 expression in disease states. Acta Biochim Pol2005, 52:273-284.
42. Li X, Leu S, Cheong A, et al. Akt2, phosphatidylinositol 3-kinase, and PTEN are in lipid rafts of intestinal cells: Role in absorption and differentiation. Gastroenterology 2004;126:122-135.
43. Simons K, Toomre D. Lipid rafts and signal transduction. Nat rev mol Cell Biol 2000;1:31-49.
44. Blikslager AT, Roberts MC, Argenzio RA. Prostaglandin-induced recovery of barrier function in porcine ileum is triggered by chloride secretion. Am J Physiol Gastrointest Liver Physiol 1999;276:G28-G36.
45. Little D, Dean RA, Young KM, et al. Phosphatidylinositol-3-kinase (PI3'K) signaling is required for prostaglandin-induced mucosal recovery in ischemia-injured porcine ileum. Am J Physiol Gastrointest Liver Physiol 2003;284:G46-56.
46. Van der Vusse GJ, Reneman RS, Van Bilsen M. Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: Possible causes and consequences. Prostaglandins Leukot Essent Fatty Acids 1997;57:85-93.
47. Heindl B, Becker BF. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC58125, aggravates postischaemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch Pharmacol 2001;363:233-40.
48. Yu Z, Ng VY, Su P, et al. Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary γ-Linolenic acid. J Pharmacol Exp Ther 2006;317:732-738.
49. Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 2005;35:347-385.
50. Krause MM, Brand MD, Krauss S, et al. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum 2003;48:1438-1444.
51. Petrescu I, Tarba C. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim Biophys Acta 1997;1318:385-394.
52. Tibble JA, Sigthorsson G, Foster R, et al. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000;35:802-807.
53. Moreno-Sanchez R, Bravo C, Vasquez C, et al. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal antiinflammatory drugs. Biochem Pharmacol 1999;57:743-752.
54. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235-243.
55. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
56. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
57. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Nat Acad Sci USA 1994;91:7355-7359.
58. Delerive P, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrin 2001;169:453-459.
59. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-424.
60. Jaradat MS, Wongsud B, Phornchirasilp S, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001;62:1587-1595.
61. Boyault S, Bianchi A, Moulin D, et al. 15-deoxy-Δ12,14- prostaglandin J2 inhibits IL-1β-induced IKK enzymatic activity and IκBα degradation in rat chondrocytes through a PPARγ- independent pathway. FEBS Letters 2004;572:33-40.
62. Nakajima A, Wada K, Miki H, et al. Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001;120:460-469.
63. Chen F, Wang M, O'Connor JP, et al. Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-κB. J Cell Biochem 2003;90:732-744.
64. Adams M, Reginato MJ, Shao D, et al. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997;272:5128-5132.
65. Feinstein DL, Spagnolo A, Akar C, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharm 2005;70:177-188.
66. Takagi T, Naito Y, Ichikawa H, et al. A PPAR-gamma ligand, 15-deoxy-Delta 12,14-prostaglandin J(2), inhibited gastric mucosal injury induced by ischemia-reperfusion in rats. Redox Rep 2004;9:376-381.
67. López-Parra M, Clària J, Titos E, et al. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ. Influence of albumin. J Hepatol 2005;42:75-81.
68. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator- activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
69. Meade EA, McIntyre TM, Zimmerman GA, et al. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274:8328-8334.
70. Sato N, Kozar RA, Zou L, et al. Peroxisome proliferator-activated receptor gamma mediates protection against cyclooxygenase-2-induced gut dysfunction in a rodent model of mesenteric ischemia/reperfusion. Shock 2005;24:462-469.
71. Sato N, Moore FA, Kone BC, et al. Differential induction of PPARγ by luminal glutamine and iNOS by luminal arginine in the rodent post ischemic small bowel. Am J Physiol Gastrointest Liver Physiol 2006;290:616-623.
72. Chen LW, Egan L, Li ZW, et al. The two faces of IKK and NF-κB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003;9:575-581.
73. Ahn KS, Aggarwal BB. Transcription factor NF-κB: A sensor for smoke and stress signals. Ann NY Acad Sci 2005;1056:218-233.
74. Hu YF, Guo Y, Cheng GF. Inhibitory effects of indomethacin and meloxicam on NF-kappa B in mouse peritoneal macrophages. Yao Xue Xue Bao 2001;36:161-164.
75. Li LC, Hou Q, Guo Y, et al. Inhibitory effect of meloxicam on human polymorphonuclear leukocyte adhesion to human synovial cell. Yao Xue Xue Bao 2002;37:103-107.
76. Callejas NA, Fernandez-Martinez A, Castrillo A, et al. Selective inhibitors of cyclooxygenase-2 delay the activation of nuclear factor KB and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide. Mol Pharmacol 2003;63:671-677.
77. Lavagno L, Gunella G, Bardelli C, et al. Anti-inflammatory drugs and tumor necrosis factor-α production from monocytes: Role of transcription factor NFκB and implication for rheumatoid arthritis therapy. Eur J Pharm 2004;501:199-208.
78. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal antiinflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-9258.
79. Poligone B, Baldwin AS. Positive and negative regulation of NF-κB by COX-2. Roles of different prostaglandins. J Biol Chem 2001;276:38658-38664.
80. Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NFκB. FASEB J 2001;15:1622-1824.
81. Callejas NA, Casado M, Bosca L, et al. Absence of nuclear factor KB inhibition by NSAIDs in hepatocytes. Hepatology 2002;35:341-348.
82. Grishin AV, Wang J, Potoka DA, et al. Lipopolysaccharide induces cyclooxygenase-2 in intestinal epithelium via a noncanonical p38 MAPK pathway. J Immunol 2006;176:580-588.
83. Kim TI, Jin SH, Kang EH, et al. The role of mitogen-activated protein kinases and their relationship with NF-κB and PPARγ in indomethacin-induced apoptosis of colon cancer cells. Ann NY Acad Sci 2002;973:241-245.
84. Shifflett DE, Jones SL, Moeser AJ, et al. Mitogen-activated protein kinases regulate COX-2 and mucosal recovery in ischemic-injured porcine ileum. Am J Physiol Gastrointest Liver Physiol 2004;286:G906-G913.
85. Naito Y, Mizushima K, Yoshikawa T. Global analysis of gene expression in gastric ischemia-reperfusion: A future therapeutic direction for mucosal protective drugs. Dig Dis Sci 2005;50Suppl 1:S45-55.
86. Locke JE, Bradbury CM, Wei SJ, et al. Indomethacin lowers the threshold thermal exposure for hyperthermic radio-sensitization and heat-shock inhibition of ionizing radiation-induced activation of NF-kappaB. Int J Radiat Biol 2002;78:493-502.
87. Lagunas L, Bradbury CM, Laszlo A, et al. Indomethacin and ibuprofen induce Hsc70 nuclear localization and activation of the heat shock response in HeLa cells. Biochem Biophys Res Commun 2004;313:863-870.
88. Nousby JN, Cahil CM, Chu B, et al. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines that induce HSP70 in human monocytes. Cytokine 1999;11:347-358.